Showing results (1511-1520 of 10,079) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|January 3, 2013
Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung diseaseOlaf Eickmeier, Nikolaus Rieber, Jonas Eckrich, et al.Current Pharmaceutical Design|January 3, 2013
Invasive aspergillosis in children and adolescentsAndreas H Groll, Dominik Schrey, Athanasios Tragiannidis, et al.Current Pharmaceutical Design|January 3, 2013
Invasive aspergillosis: new insights into disease, diagnostic and treatmentMeinolf Karthaus, Dieter BuchheidtCurrent Pharmaceutical Design|January 3, 2013
Immunotherapy in invasive fungal infection--focus on invasive aspergillosisThomas Lehrnbecher, Markus Kalkum, Jackson Champer, et al.Current Pharmaceutical Design|January 16, 2013
The role of fibrate treatment in dyslipidemia: an overviewNiki Katsiki, Dragana Nikolic, Giuseppe Montalto, et al.Current Pharmaceutical Design|January 16, 2013
The role of niacin in lipid-lowering treatment: are we aiming too high?Ioanna Gouni-Berthold, Heiner K BertholdCurrent Pharmaceutical Design|January 16, 2013
Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemiasMichael S Kostapanos, Evangelos C Rizos, Nikolaos Papanas, et al.Current Pharmaceutical Design|February 28, 2012
Inflammation-induced thrombosis: mechanisms, disease associations and managementKenan Aksu, Ayhan Donmez, Gokhan KeserCurrent Pharmaceutical Design|February 28, 2012
The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritisMike J L Peters, Alper M van Sijl, Alexandre E Voskuyl, et al.Current Pharmaceutical Design|February 28, 2012
Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trialsAlexios S Antonopoulos, Marios Margaritis, Regent Lee, et al.Pageof 1,008